GeneDx Holdings Corp. 8-K

What Happened GeneDx Holdings Corp. filed a Form 8-K on May 4, 2026 announcing results for the quarter ended March 31, 2026, and furnished a press release and an earnings presentation. The company changed the presentation in its consolidated statements of operations by combining the previously separate “selling and marketing” and “general and administrative” line items into a single “selling, general and administrative” line item effective for the quarter ended March 31, 2026. GeneDx also modified its non‑GAAP adjusted net income (loss) methodology to add an adjustment for non‑core lease costs related to vacant laboratory and office space in Connecticut. Katherine Stueland, CEO, signed the filing.

Key Details

• Form 8‑K filed May 4, 2026; press release and earnings presentation furnished as exhibits.
• Presentation change: “selling and marketing” + “general and administrative” → single “selling, general and administrative” line item starting Q1 2026; this is a presentation change only and does not affect GAAP results.
• Non‑GAAP change: adjusted net income (loss) now includes non‑core lease costs (vacant CT lab/office occupancy expenses) beginning Q1 2026.
• Prior periods: the company furnished recast unaudited financial information for fiscal 2025 and its interim periods to reflect the reclassification and the recalculated adjusted net income; this is not a restatement and does not change previously reported GAAP results.

Why It Matters These changes affect how GeneDx reports operating line items and adjusts non‑GAAP earnings, improving comparability going forward. Investors should note that the presentation change does not alter GAAP earnings, but the expanded adjusted net income adjustment (adding non‑core lease costs) could reduce reported non‑GAAP earnings compared with prior disclosures. Review the recast supplemental financials and the May 4 press release/earnings presentation for the actual revenue, profit/loss figures and management commentary.